Table 2. Published case reports of furosemide-related pancreatitis.

STUDY	AGE, Y	SEX	COMORBIDITY	DOSAGE	LATENCY PERIOD	OUTCOME	RECHALLENGE	RECURRENCE	OUTPATIENT OR INPATIENT	CONFOUNDERS
Wilson et al5	23	M	Malignant HTN, CHF, emphysema	40 mg/d	3 wk	Recovery	No	No	Inpatient	Tetracycline, methyldopa; alcoholism
Jones and Oelbaum6	64	F	HTN, AMI, CHF	40 mg/d	7 wk	Recovery	Yes	Yes	Inpatient	Dyslipidemia
Strunge7	53	F	CHF	1000 mg/d	NA	Death	No	No	Inpatient	Ventricular fibrillation
	72	F	AMI	240 mg/d	NA	Death	No	No	Inpatient	Cardiogenic shock
Buchanan and Cane8	46	M	DM	500 mg, single dose	12 h	Death	No	No	Inpatient	Alcoholism
	56	M	CHF	250 mg, single dose	8 h	Recovery	No	No	Inpatient	Alcoholism
	49	M	Varices	250 mg, single dose	18 h	Recovery	No	No	Inpatient	Alcoholism
Stenvinkel and Alvestrand9	34	M	CHF	750 mg/d	1 d	Recovery	Yes	Yes	Inpatient	Captopril
Call et al10	41	F	HTN	40 mg/d	3 d	Recovery	Yes	Yes	Inpatient	Dyslipidemia
Juang et al11	57	F	DCM, SSS, HTN, Hashimoto thyroiditis	80 mg/d	5 wk	Recovery	Yes	Yes	Inpatient	Dyslipidemia, sulfonamide allergy
Current case	60	M	HTN, MG	40 mg/d	1 d	Recovery	No	No	Outpatient	Dyslipidemia

AMI—acute myocardial infarction, CHF—congestive heart failure, DCM—dilated cardiomyopathy, DM—diabetes mellitus, F—female, HTN—hypertension, M—male, MG—membranous glomerulopathy, NA—not applicable, SSS—sick sinus syndrome.